Vitamin D levels in Indian systemic lupus erythematosus patients: Association with disease activity index and interferon alpha

Arthritis Research and Therapy

Volumn 16, Issue 1, 2014, Pages

  Mandal, Manamita ^a   Tripathy, Rina ^a   Panda, Aditya K ^b   Pattanaik, Sarit S ^a   Dakua, Simanchal ^a   Pradhan, Anjan K ^b   Chakraborty, Soumen ^b   Ravindran, Balachandran ^b   Das, Bidyut K ^a  

^a SCB MEDICAL COLLEGE   (India)

^b INSTITUTE OF LIFE SCIENCES   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; COLECALCIFEROL; VITAMIN D;

ADULT; ARTHRITIS; ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION; HUMAN; INDIAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; MOUTH ULCER; MYOCARDITIS; NEPHRITIS; PHENOTYPE; PHOTOSENSITIVITY; PROTEIN BLOOD LEVEL; RASH; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SLEDAI; SYSTEMIC LUPUS ERYTHEMATOSUS; VASCULITIS; VITAMIN BLOOD LEVEL; VITAMIN SUPPLEMENTATION; BIOSYNTHESIS; BLOOD; IMMUNOLOGY; INDIA; VITAMIN D DEFICIENCY;

ADULT; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INDIA; INTERFERON-ALPHA; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; VITAMIN D; VITAMIN D DEFICIENCY;

EID: 84896724122     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar4479     Document Type: Article

References (49)

1. Crispin JC, Liossis SN, Kis-Toth K, Lieberman LA, Kyttaris VC, Juang YT, Tsokos GC. Pathogenesis of human systemic lupus erythematosus: recent advances. Trends Mol Med 2010, 16:47-57. 10.1016/j.molmed.2009.12.005, 2823952, 20138006.
2. Tsokos GC. Systemic lupus erythematosus. N Engl J Med 2011, 365:2110-2121. 10.1056/NEJMra1100359, 22129255.
3. Gatenby P, Lucas R, Swaminathan A. Vitamin D deficiency and risk for rheumatic diseases: an update. Curr Opin Rheumatol 2013, 25:184-191. 10.1097/BOR.0b013e32835cfc16, 23370372.
4. Pludowski P, Holick MF, Pilz S, Wagner CL, Hollis BW, Grant WB, Shoenfeld Y, Lerchbaum E, Llewellyn DJ, Kienreich K, Soni M. Vitamin D effects on musculoskeletal health, immunity, autoimmunity, cardiovascular disease, cancer, fertility, pregnancy, dementia and mortality-a review of recent evidence. Autoimmun Rev 2013, 12:976-989. 10.1016/j.autrev.2013.02.004, 23542507.
5. Yang CY, Leung PS, Adamopoulos IE, Gershwin ME. The implication of vitamin D and autoimmunity: a comprehensive review. Clin Rev Allergy Immunol 2013, 45:217-226. 10.1007/s12016-013-8361-3, 23359064.
6. Munger KL, Levin LI, Hollis BW, Howard NS, Ascherio A. Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. JAMA 2006, 296:2832-2838. 10.1001/jama.296.23.2832, 17179460.
7. Cantorna MT, Hayes CE, DeLuca HF. 1,25-Dihydroxycholecalciferol inhibits the progression of arthritis in murine models of human arthritis. J Nutr 1998, 128:68-72.
8. Mathieu C, Waer M, Laureys J, Rutgeerts O, Bouillon R. Prevention of autoimmune diabetes in NOD mice by 1,25 dihydroxyvitamin D3. Diabetologia 1994, 37:552-558. 10.1007/BF00403372, 7926338.
9. Cantorna MT, Munsick C, Bemiss C, Mahon BD. 1,25-Dihydroxycholecalciferol prevents and ameliorates symptoms of experimental murine inflammatory bowel disease. J Nutr 2000, 130:2648-2652.
10. Lemire JM, Archer DC. 1,25-dihydroxyvitamin D3 prevents the in vivo induction of murine experimental autoimmune encephalomyelitis. J Clin Invest 1991, 87:1103-1107. 10.1172/JCI115072, 329907, 1705564.
11. Lemire JM, Ince A, Takashima M. 1,25-Dihydroxyvitamin D3 attenuates the expression of experimental murine lupus of MRL/l mice. Autoimmunity 1992, 12:143-148. 10.3109/08916939209150321, 1617111.
12. Abe J, Nakamura K, Takita Y, Nakano T, Irie H, Nishii Y. Prevention of immunological disorders in MRL/l mice by a new synthetic analogue of vitamin D3: 22-oxa-1 alpha,25-dihydroxyvitamin D3. J Nutr Sci Vitaminol 1990, 36:21-31. 10.3177/jnsv.36.21, 2163440.
13. Vaisberg MW, Kaneno R, Franco MF, Mendes NF. Influence of cholecalciferol (vitamin D3) on the course of experimental systemic lupus erythematosus in F1 (NZBxW) mice. J Clin Lab Anal 2000, 14:91-96. 10.1002/(SICI)1098-2825(2000)14:3<91::AID-JCLA2>3.0.CO;2-O, 10797606.
14. Kamen DL, Cooper GS, Bouali H, Shaftman SR, Hollis BW, Gilkeson GS. Vitamin D deficiency in systemic lupus erythematosus. Autoimmun Rev 2006, 5:114-117. 10.1016/j.autrev.2005.05.009, 16431339.
15. Borba VZ, Vieira JG, Kasamatsu T, Radominski SC, Sato EI, Lazaretti-Castro M. Vitamin D deficiency in patients with active systemic lupus erythematosus. Osteoporos Int 2009, 20:427-433. 10.1007/s00198-008-0676-1, 18600287.
16. Hamza RT, Awwad KS, Ali MK, Hamed AI. Reduced serum concentrations of 25-hydroxy vitamin D in Egyptian patients with systemic lupus erythematosus: relation to disease activity. Med Sci Monit 2011, 17:CR711-CR718. 3628141, 22129903.
17. Vacca A, Cormier C, Piras M, Mathieu A, Kahan A, Allanore Y. Vitamin D deficiency and insufficiency in 2 independent cohorts of patients with systemic sclerosis. J Rheumatol 2009, 36:1924-1929. 10.3899/jrheum.081287, 19648299.
18. Holick MF. Vitamin D deficiency. N Engl J Med 2007, 357:266-281. 10.1056/NEJMra070553, 17634462.
19. Hewison M, Zehnder D, Bland R, Stewart PM. 1alpha-hydroxylase and the action of vitamin D. J Mol Endocrinol 2000, 25:141-148. 10.1677/jme.0.0250141, 11013342.
20. Malaviya AN, Singh RR, Singh YN, Kapoor SK, Kumar A. Prevalence of systemic lupus erythematosus in India. Lupus 1993, 2:115-118. 10.1177/096120339300200209, 8330032.
21. Kumar A, Malaviya AN, Singh RR, Singh YN, Adya CM, Kakkar R. Survival in patients with systemic lupus erythematosus in India. Rheumatol Int 1992, 12:107-109. 10.1007/BF00290264, 1411089.
22. Murali R, Jeyaseelan L, Rajaratnam S, John L, Ganesh A. Systemic lupus erythematosus in Indian patients: prognosis, survival and life expectancy. Natl Med J India 1997, 10:159-164.
23. Vijay J, Kapil U. Vitamin d deficiency and its health consequences - a review. Indian J. Community Health 2012, 24:232-236.
24. Panda AK, Parida JR, Tripathy R, Pattanaik SS, Ravindran B, Das BK. Low producer MBL genotypes are associated with susceptibility to systemic lupus erythematosus in Odisha, India. Hum Immunol 2013, 74:114-119.
25. Panda AK, Parida JR, Tripathy R, Pattanaik SS, Ravindran B, Das BK. Mannose binding lectin: a biomarker of systemic lupus erythematosus disease activity. Arthritis Res Ther 2012, 14:R218. 10.1186/ar4057, 3580530, 23068019.
26. Panda AK, Pattanaik SS, Tripathy R, Das BK. TLR-9 promoter polymorphisms (T-1237C and T-1486C) are not associated with systemic lupus erythematosus: A case control study and meta-analysis. Hum Immunol 2013, 74:1672-1678. 10.1016/j.humimm.2013.08.006, 23974051.
27. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997, 40:1725.
28. Danchenko N, Satia JA, Anthony MS. Epidemiology of systemic lupus erythematosus: a comparison of worldwide disease burden. Lupus 2006, 15:308-318. 10.1191/0961203306lu2305xx, 16761508.
29. Palmer P, Tovey MG, Raschilas F, Brassart L, Meritet JF, Porcher R, Lebon P. Type I interferon subtypes produced by human peripheral mononuclear cells from one normal donor stimulated by viral and non-viral inducing factors. Eur Cytokine Netw 2007, 18:108-114.
30. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 2001, 25:402-408. 10.1006/meth.2001.1262, 11846609.
31. Ronnblom L. Potential role of IFN alpha in adult lupus. Arthritis Res Ther 2010, 12:S3. 10.1186/ar2884, 2991776, 20392290.
32. Niewold TB, Clark DN, Salloum R, Poole BD. Interferon alpha in systemic lupus erythematosus. J Biomed Biotechnol 2010, 2010:948364. 2896914, 20652065.
33. Bikle DD. Vitamin D and immune function: understanding common pathways. Curr Osteoporos Rep 2009, 7:58-63. 10.1007/s11914-009-0011-6, 19631030.
34. Cutolo M, Otsa K. Review: vitamin D, immunity and lupus. Lupus 2008, 17:6-10. 10.1177/0961203307085879, 18089676.
35. Clemens TL, Adams JS, Henderson SL, Holick MF. Increased skin pigment reduces the capacity of skin to synthesise vitamin D3. Lancet 1982, 1:74-76.
36. Ruiz-Irastorza G, Egurbide MV, Olivares N, Martinez-Berriotxoa A, Aguirre C. Vitamin D deficiency in systemic lupus erythematosus: prevalence, predictors and clinical consequences. Rheumatology (Oxford) 2008, 47:920-923. 10.1093/rheumatology/ken121, 18411213.
37. Muller K, Kriegbaum NJ, Baslund B, Sorensen OH, Thymann M, Bentzen K. Vitamin D3 metabolism in patients with rheumatic diseases: low serum levels of 25-hydroxyvitamin D3 in patients with systemic lupus erythematosus. Clin Rheumatol 1995, 14:397-400. 10.1007/BF02207671, 7586974.
38. Chen TC, Chimeh F, Lu Z, Mathieu J, Person KS, Zhang A, Kohn N, Martinello S, Berkowitz R, Holick MF. Factors that influence the cutaneous synthesis and dietary sources of vitamin D. Arch Biochem Biophys 2007, 460:213-217. 10.1016/j.abb.2006.12.017, 2698590, 17254541.
39. Toloza SM, Cole DE, Gladman DD, Ibanez D, Urowitz MB. Vitamin D insufficiency in a large female SLE cohort. Lupus 2010, 19:13-19. 10.1177/0961203309345775, 19897520.
40. Terrier B, Derian N, Schoindre Y, Chaara W, Geri G, Zahr N, Mariampillai K, Rosenzwajg M, Carpentier W, Musset L, Piette JC, Six A, Klatzmann D, Saadoun D, Patrice C, Costedoat-Chalumeau N. Restoration of regulatory and effector T cell balance and B cell homeostasis in systemic lupus erythematosus patients through vitamin D supplementation. Arthritis Res Ther 2012, 14:R221. 10.1186/ar4060, 3580532, 23075451.
41. Ritterhouse LL, Crowe SR, Niewold TB, Kamen DL, Macwana SR, Roberts VC, Dedeke AB, Harley JB, Scofield RH, Guthridge JM, James JA. Vitamin D deficiency is associated with an increased autoimmune response in healthy individuals and in patients with systemic lupus erythematosus. Ann Rheum Dis 2011, 70:1569-1574. 3149865, 21586442.
42. Cantorna MT, Mahon BD. Mounting evidence for vitamin D as an environmental factor affecting autoimmune disease prevalence. Exp Biol Med (Maywood) 2004, 229:1136-1142.
43. Chambers ES, Hawrylowicz CM. The impact of vitamin D on regulatory T cells. Curr Allergy Asthma Rep 2011, 11:29-36. 10.1007/s11882-010-0161-8, 21104171.
44. Kirou KA, Lee C, George S, Louca K, Peterson MG, Crow MK. Activation of the interferon-alpha pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease. Arthritis Rheum 2005, 52:1491-1503. 10.1002/art.21031, 15880830.
45. Dall'era MC, Cardarelli PM, Preston BT, Witte A, Davis JC. Type I interferon correlates with serological and clinical manifestations of SLE. Ann Rheum Dis 2005, 64:1692-1697. 1755300, 15843451.
46. Feng X, Wu H, Grossman JM, Hanvivadhanakul P, FitzGerald JD, Park GS, Dong X, Chen W, Kim MH, Weng HH, Furst DE, Gorn A, McMahon M, Taylor M, Brahn E, Hahn BH, Tsao BP. Association of increased interferon-inducible gene expression with disease activity and lupus nephritis in patients with systemic lupus erythematosus. Arthritis Rheum 2006, 54:2951-2962. 10.1002/art.22044, 16947629.
47. Bennett L, Palucka AK, Arce E, Cantrell V, Borvak J, Banchereau J, Pascual V. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med 2003, 197:711-723. 10.1084/jem.20021553, 2193846, 12642603.
48. Reichel H, Koeffler HP, Tobler A, Norman AW. 1 alpha,25-dihydroxyvitamin D3 inhibits gamma-interferon synthesis by normal human peripheral blood lymphocytes. Proc Natl Acad Sci U S A 1987, 84:3385-3389. 10.1073/pnas.84.10.3385, 304875, 3033646.
49. Griffin MD, Lutz WH, Phan VA, Bachman LA, McKean DJ, Kumar R. Potent inhibition of dendritic cell differentiation and maturation by vitamin D analogs. Biochem Biophys Res Commun 2000, 270:701-708. 10.1006/bbrc.2000.2490, 10772887.